The Claim
Sodium-glucose co-transporter-2 inhibitors (SGLT2is) are associated with a mean loss of 1.04 kg of lean body mass in adults with obesity or type 2 diabetes over 8 to 102 weeks of treatment, and this loss represents approximately 21% of total weight loss.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with obesity or type 2 diabetes taking SGLT2 inhibitors, lean body mass decreases by an average of 1.04 kg over 8 to 102 weeks, accounting for about 21% of the total weight lost during treatment.
See the scientific wording
Sodium-glucose co-transporter-2 inhibitors (SGLT2is) are associated with a mean loss of 1.04 kg of lean body mass in adults with obesity or type 2 diabetes over 8 to 102 weeks of treatment, which represents approximately 21% of total weight loss, indicating that lean mass reduction is a consistent, though smaller, component of weight reduction with these agents compared to GLP-1RAs.
When the kidneys can't reabsorb sugar, excess sugar leaves the body in urine, creating a calorie deficit. To make more sugar for energy, the body breaks down muscle protein to extract amino acids, which the liver and kidneys use to produce glucose. This process reduces muscle mass over time.
What the research says
1 studyThis study found that when people with obesity or diabetes take SGLT2 inhibitor drugs, they lose about 1 kilogram of muscle and lean tissue, which is roughly one-fifth of all the weight they lose — just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.